Response to: ‘Comment on: ‘Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab’ by Eric Morand et al’ by Isenberg

The authors thank Professor Isenberg for pointing out a drafting error on the manuscript reporting the use of the Lupus Low Disease Activity State (LLDAS) in the anifrolumab phase II trial data set. The British Isles Lupus Assessment Group (BILAG) instrument does indeed document gastrointestinal disease activity, while Systemic Lupus Erythematosis (SLE) Disease Activity Index 2000 (SLEDAI-2K) does not. This error does not impact on the findings of the published paper, or the intended meaning of the sentence in which this error occurred, which was a discussion of the need for evidence that the physician global assessment adequately captures gastrointestinal activity in SLE.

Eric F Morand,1 Teodora Trasieva,2 Anna Berglind,2 Gabor Illei3
1School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia
2AstraZeneca, Gothenburg, Sweden
3Clinical Development, Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, USA

Correspondence to: Professor Eric F Morand, School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton Victoria 3168, Australia; eric.morand@monash.edu

Handling editor: Josef S Smolen

Contributors: EFM wrote the text, with approval from the authors.

Competing interests: None declared.

Provenance and peer review: Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.


Received 1 October 2018
Revised 2 October 2018
Accepted 6 October 2018
Published Online First 29 October 2018

REFERENCES